Results 71 to 80 of about 2,019 (146)

Identifying potential monkeypox virus inhibitors: an in silico study targeting the A42R protein

Frontiers in Cellular and Infection Microbiology
Monkeypox (now Mpox), a zoonotic disease caused by the monkeypox virus (MPXV) is an emerging threat to global health. In the time span of only six months, from May to October 2022, the number of MPXV cases breached 80,000 and many of the outbreaks ...
Carolyn N. Ashley, Emmanuel Broni, Chanyah M. Wood, Chanyah M. Wood, Tunmise Okuneye, Tunmise Okuneye, Mary-Pearl T. Ojukwu, Mary-Pearl T. Ojukwu, Mary-Pearl T. Ojukwu, Qunfeng Dong, Qunfeng Dong, Carla Gallagher, Whelton A. Miller, Whelton A. Miller   +13 more
doaj   +1 more source

Tecovirimat-Related Substance: Characterization, Hirshfeld Analysis, Theoretical Study, In Silico Toxicity Assessment

Molecules
Crystal structures of 4-(trifluoromethyl)benzene-1-carbohydrazide (1), 4-(trifluoromethyl)-N’-{[4-(trifluoromethyl)phenyl]carbonyl}benzohydrazide (2) and (1R,2S,6R,7S,8S,10R)-4-({[4-(trifluoromethyl)phenyl]carbonyl}amino)-4-azatetracyclo [5.3.2.08,10.02 ...
Fengfeng Wang, Xiaowen Hu, Caiyu Zhang, Lin Luan, Zhengzheng Zhou, Yang Liu   +5 more
doaj   +1 more source

The Role of Tecovirimat in the Management of Monkeypox

Bioscientia Medicina : Journal of Biomedicine and Translational Research
Monkeypox is a self-limited disease with symptoms that disappear within 14 to 21 days. Clinical management of monkeypox includes general supportive care and the use of antivirals that have activity against the monkeypox virus. This literature study aims to describe the role of tecovirimat in the management of monkeypox. Tecovirimat is an antiviral drug
Ari Dwi Prasetyo, null Harun Hudari, null Mega Permata, null Nelda Aprilia Salin   +3 more
openaire   +1 more source

Concurrent Mpox and HSV-1 Proctitis in a Young Male With AIDS: A Case Report of Treatment Failure

Case Reports in Infectious Diseases
Managing the mpox in patients with advanced HIV infection and coinfections poses significant challenges. This report discusses a young male with advanced HIV (CD4 count 28) and severe concurrent mpox and HSV-1 proctitis.
Mikhail Sukhoroslov, Fouad Kaddour-Hocine, Muhammad Hammad Ashraf, Navya Mandalapu, Shivani Bansal, Matthew Peachey   +5 more
doaj   +1 more source

Tecovirimat [PDF]

, 2020
openaire   +1 more source

Mechanisms of Tecovirimat Antiviral Activity and Poxvirus Resistance

Abstract Mpox is a zoonotic disease endemic in central and west Africa. However, since 2022, human-adapted mpox virus (MPXV) strains are causing large outbreaks spreading outside these regions, leading the World Health Organization to declare public health emergency twice. Tecovirimat, the most widely used drug to treat these infections, blocks
Vernuccio, Riccardo, Martínez León, Alejandro, Poojari, Chetan, Buchrieser, Julian, Selverian, Christopher, Jaleta, Yakin, Meola, Annalisa, Guivel-Benhassine, Florence, Porrot, Françoise, Haouz, Ahmed, Chevreuil, Maelen, Raynal, Bertrand, Mercer, Jason, Simon-Loriere, Etienne, Chandran, Karti, Schwartz, Olivier, Hub, Jochen S., Guardado-Calvo, Pablo   +17 more
openaire   +4 more sources

The next generation of orthopoxvirus antivirals: preparing for future threats. [PDF]

Future Med Chem
Jagtap AD, Yang Z, Wang Z.
europepmc   +1 more source

Tecovirimat treatment of clade II mpox: a virological analysis of a randomised, double-blind, phase 3 trial. [PDF]

Lancet Microbe
Vyshenska D, Reed JC, Roychoudhury P, Zheng L, Olefsky M, Ritz J, McCarthy C, Saha PT, Hao L, Mills MG, Shea A, Nunley BE, Javan AC, Brooks KM, Nachman S, Eron J, Gandhi RT, Currier J, Fischer WA, Zucker J, Wilkin T, Greninger AL, ACTG A5418–STOMP protocol team.   +22 more
europepmc   +1 more source

Treatment of mpox with tecovirimat under expanded access use in the Central African Republic. [PDF]

Int J Infect Dis
Bourner J, Mbrenga F, Pesonel E, Soumah A, Garba-Ouangole S, Farra E, Lemon C, Malaka C, Dunning J, Rojek A, Boum Y, Horby P, Nakouné E, Olliaro P.   +13 more
europepmc   +1 more source

Differential pathogenesis and antiviral treatment outcomes of MPXV clade Ib and clade IIb in a BALB/c mouse model. [PDF]

Emerg Microbes Infect
Feng Y, Shen C, Jia P, Peng B, Yang W, Chen S, Peng Y, Liang X, Zhang S, Chang F, Lin Y, Zhang M, Liu Y, Li B, Wang F, Yang Y.   +15 more
europepmc   +1 more source